GlassScriptPhysician profile
Darin L Christensen
NPI 1922093772
$11,772.97
in general payments reported to CMS, 2019-2025
28 companies · $2,544 in 2025
The $2,544 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,623 · 2020: $1,450 · 2021: $1,545 · 2022: $1,183 · 2023: $1,443 · 2024: $1,985 · 2025: $2,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,967 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,967.13 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $1,817.53 | 2019-2025 | Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $1,577.36 | 2019-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,516.72 | 2020-2025 | Caplyta |
| Abbvie INC. | $954.97 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $941.74 | 2021-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $810.51 | 2019-2022 | |
| Neuronetics, INC. | $505.88 | 2019-2025 | Neurostar Tms Therapy System |
| Takeda Pharmaceuticals U.S.A., INC. | $472.81 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $451.96 | 2019-2023 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $447.85 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $444.38 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $347.22 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $309.16 | 2021-2025 | Uzedy |
| Alkermes, INC. | $277.59 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Neurocrine Biosciences, INC. | $155.53 | 2020-2025 | Ingrezza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $130.22 | 2019-2023 | Sublocade |
| Axsome Therapeutics, INC. | $117.03 | 2024-2025 | Auvelity |
| Eisai INC. | $87.21 | 2020-2021 | |
| Shire North American Group INC | $85.64 | 2019 | |
| Corium, LLC | $64.48 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.76 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $48.66 | 2021 | |
| Adlon Therapeutics L.P. | $47.24 | 2020-2021 | |
| Noven Therapeutics, LLC | $32.07 | 2021 | |
| Collegium Pharmaceutical, INC. | $21.45 | 2025 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $21.10 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.93 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.97 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.